Sumanta K. Pal, MD, on Urothelial Cancer: Results From the CheckMate 275 Trial
2016 ESMO CongressSumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatment. Follow him on Twitter: @montypal
Related Videos
Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)
Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung ca...
Tony Mok, MD, on NSCLC: Results of the IMPRESS Study
Tony Mok, MD, of The Chinese University of Hong Kong, discusses the final overall survival analysis from this trial on gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive...
Arjun V. Balar, MD, on Urothelial Cancer: Results From KEYNOTE-052
Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center, discusses preliminary phase II study findings on pembrolizumab as first-line therapy for advanced/unresectable or metastatic u...
Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial (French Language Version)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses in French phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after n...
Toni K. Choueiri, MD, on Metastatic RCC: Results From the ALLIANCE A031203 Trial
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell ca...
